**“Staying Forever Young”: H2 Global Group Sets a Hydrogen Standard in Longevity**
From “Blue Zones” to a Modern, Innovative Approach to Geriatrics
Today’s longevity concept draws inspiration both from the so-called “Blue Zones”—regions with a high proportion of long-living populations—and from modern geroscience, which describes aging as a biological process influenced, among other factors, by oxidative stress, chronic inflammation, and mitochondrial dysfunction. According to numerous scientific studies, molecular hydrogen plays a highly significant role in these mechanisms.
Based on a wide range of clinical studies and scientific publications, molecular hydrogen acts as a selective antioxidant, exhibits anti-inflammatory and mitochondria-protective effects, and in both preclinical and clinical research shows strong potential in the areas of cognitive health, neurodegenerative diseases, physical performance, and recovery. Hydrogen is not a miraculous “elixir of immortality,” but rather a promising bioactive molecule that fits well within the philosophy of safe, long-term, and measurable support of lifespan in optimal health and physical condition.
H2 Global Group – A Czech Innovator in Molecular Hydrogen
H2 Global Group, headquartered in the Czech Republic, was founded with the ambition to build a comprehensive technological and product ecosystem around molecular hydrogen. The group brings together physicians, scientists, and pharmacists, maintains its own R&D capabilities, and closely cooperates with Professor Shigeo Ohta of Japan, widely regarded as the founder of hydrogen biomedicine and a co-owner of the company.
The company’s portfolio includes solutions for medicine and neuroscience, beauty and wellness, spa and medical centers, sports teams, and corporate wellness programs.
H2 Medical Technologies and Controlled Hydrogen Therapy
A key role within the MedTech segment of the group is played by subsidiary H2 Medical Technologies. The company develops and manufactures safe and effective molecular hydrogen generators, based on advanced SPE/PEM technology, capable of producing ultra-pure hydrogen for safe inhalation in both clinical and home environments.
A major milestone is the prototype of the world’s first hydrogen generator intended for medical device registration, with which the company aims to register the world’s first hydrogen-based medical device. This device will also be used in the first clinical study in the Czech Republic approved by the State Institute for Drug Control (SÚKL), focused on molecular hydrogen inhalation in individuals with mild cognitive impairment (MCI)—a condition that often precedes Alzheimer’s dementia.
The study will begin in early 2026 and aims to evaluate the safety and efficacy of controlled hydrogen therapy in MCI patients. The study is currently in the recruitment phase, and suitable volunteers are being sought.
Basic eligibility criteria include:
-
age 50–80 years,
-
generally good health,
-
diagnosis of mild cognitive impairment or mild-to-moderate dementia,
-
preferably residence in Ostrava or the surrounding area, where the study will take place.
Participation does not guarantee any health benefit and should not be considered a replacement for standard treatment. Interested individuals may apply by December 23, 2025, at:
📧 david.skoloudik@H2medical.com
This step moves molecular hydrogen from the realm of a complementary wellness tool toward the position of a serious medical instrument of the near future, with potential not only in cognitive health and dementia prevention.
The study builds directly on the European patent EP3701956B1, “Prophylactic or Therapeutic Agent for Dementia,” authored by Professor Ohta and held by H2 Global Group. The patent describes the use of molecular hydrogen in neurodegenerative diseases, including dementia, giving the Czech Republic a unique global position.
H2 Longevity® Center in Ostrava
Building on successful scientific research, H2 Longevity® Center Ostrava has now opened. This next-generation longevity center combines:
-
molecular hydrogen inhalation using devices from H2 Medical Technologies,
-
light therapy,
-
hydrogen hydration through H2 Premium Hydrogen Water,
-
specialized dietary supplements containing molecular hydrogen,
-
education in regeneration and healthy longevity.
The center functions as a showroom for distributors, investors, and partners, as well as a facility for end customers. The accumulated know-how will be used to develop a network of partner-based H2 Longevity® concepts in other cities and countries.
A Strategic Global Partner with a Unique Hydrogen Solution
A significant part of the business also lies in cooperation with partners wishing to launch their own premium longevity product lines based on molecular hydrogen. Interest is growing across Europe and other regions from medical centers, wellness hotels, private clinics, and facilities focused on biohacking, longevity, body care, and regeneration.
Partners value the ability to create their own premium brand, while leveraging an established portfolio. H2 Global Group thus acts as a strategic global partner—not only a manufacturer, but a segment leader shaping the direction of hydrogen technologies, actively supporting brand building and partner growth.
The Hydrogen Pillar of Longevity
H2 Global Group offers partners the opportunity to build a comprehensive hydrogen-based care system, emphasizing maximum safety and therapeutic effectiveness. The system includes:
-
professional training in installation, handling, and use of hydrogen inhalation devices,
-
proven procedures and protocols,
-
integration of hydrogen water into daily hydration routines,
-
dietary hydrogen supplements to enhance therapeutic effects,
-
full technical support, including warranty and post-warranty service.
The system is modular and scalable, adaptable to individual client needs and local market conditions, while being supported by both scientific and practical experience.
An Opportunity for Service Providers, Distributors, and Investors
For partners in healthcare, wellness, spa, and cosmetics, H2 Global Group represents an opportunity to help establish a new standard in the rapidly growing longevity segment—from local hydrogen zones in clinics and hotels to full private-label product portfolios.
For investors, the appeal lies in the combination of:
-
proprietary medical R&D and international patent protection,
-
regulated clinical research,
-
global scalability through exclusive partnerships and licensing models,
-
and a powerful macro-trend where longevity, prevention, and health optimization are becoming core consumer and investment themes of the next decade.
H2 Global Group is expanding its partner network and entering key international markets, offering cooperation opportunities to investors and strategic partners who want to participate in building a modern global longevity infrastructure based on a proven and functional hydrogen solution.
If you seek to include cutting-edge hydrogen technologies in your portfolio, build a respected brand, and participate in the growth of an exceptionally promising global segment, now is the right moment to join.
Public Availability of the Press Release
The press release is publicly available on:
(protext.cz, barrandov.tv, ceskenoviny.cz, metro.cz, and other listed media outlets)
Company Contact
H2 Global Group
🌐 www.H2Global.group
🌐 www.H2Vibe.cz
🌐 www.H2Invest.cz
Source: H2 Global Group
ČTK Connect provides an accompanying image package available via www.protext.cz
